PIK3CA and cancer: Some questions remain: (1) are the associations valid across multiple cancer centers in different regions and different demographics, (2) can ddPCR of the PIK3CA mutation be implemented for accurate and affordable disease monitoring, and (3) can an appropriate PIK3CA inhibitor improve outcomes for a late stage of cancer with PIK3CA mutation detectable?